Table 1.
Major murine models of HB.
Model | Attributes | Deficits | Primary References |
---|---|---|---|
Subcutaneous model | Tumors easily implanted and monitored | Model does not accurately recapitulate tumor microenvironment and vascularization | [15,17] |
Splenic injection model | First published model of intrahepatic tumorigenesis | Tumors grow as small, multifocal nodules, which makes quantifying tumor burden difficult | [8,17] |
Intrahepatic model | Tumors recapitulate liver microenvironment and show expression of genes and proteins indicative of standard disease | Use of cell lines grown extensively in vitro | [18,19] |
Subcutaneous PDX model | Fresh patient samples more closely resemble primary disease | Model does not accurately recapitulate tumor microenvironment and vascularization | [20,21,22,23] |
Intrahepatic PDX model | Fresh patient samples closely resemble primary disease and tumors recapitulate liver microenvironment | Limited access to patient samples for model generation | [24] |
LIN28B GEM model | Use of immunocompetent animals and specific exploration of LIN28B | Only models LIN28B overexpressing tumors | [25] |
myc/CTNNB1 GEM model | Use of immunocompetent animals and specific exploration of myc and CTNNB1 | Less than half of animals develop tumors and most do not survive long after birth for further studies | [26] |
Prom1 Cre-recombination GEM model | Facilitates studies of tumor initiation during development | Not a liver-specific GEM model | [27] |
CTNNB1/Yap-1 hydrodynamic tail vein injection/Sleeping Beauty transposon model | Manipulation of genes of interest without the work required for generation of a GEM model | Most animals develop nodules that eventually encompass the entire liver with tumor, which may make quantifying tumor burden difficult | [28] |